Graftys Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • M&A

Graftys General Information

Description

Developer of synthetic bone biomaterials designed to be used for reconstructive orthopedic surgery. The company offers a range of innovative, safe, and fully injectable calcium phosphate bone graft substitutes designed to target specific clinical applications, enabling patients to get standard products for bone reconstructive and trauma surgery.

Contact Information

Website
www.graftys.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 415 Rue Claude Nicolas ledoux
  • Cedex 3
  • 13854 Aix En Provence
  • France
+33 04
Primary Industry
Surgical Devices
Other Industries
Biotechnology
Therapeutic Devices
Corporate Office
  • 415 Rue Claude Nicolas ledoux
  • Cedex 3
  • 13854 Aix En Provence
  • France
+33 04

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Graftys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Jun-2024 Completed Generating Revenue
8. Later Stage VC 01-Jul-2022 Completed Generating Revenue
7. Later Stage VC 01-Feb-2019 Completed Generating Revenue
6. Later Stage VC (Series C) 26-Apr-2011 Completed Generating Revenue
5. Later Stage VC 08-Nov-2010 Completed Generating Revenue
4. Early Stage VC 29-May-2009 Completed Startup
3. Early Stage VC 03-Jun-2008 Completed Startup
2. Early Stage VC 16-Mar-2007 $1.98M $1.98M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Graftys’s complete valuation and funding history, request access »

Graftys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Preference
Preference
Preference 74,801 $1.395599 $10.47 $10.47 1x $10.47 2.68%
Preference 239,822 $1.395599 $8.73 $8.73 1x $8.73 8.59%
To view Graftys’s complete cap table history, request access »

Graftys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of synthetic bone biomaterials designed to be used for reconstructive orthopedic surgery. The company offers a
Surgical Devices
Aix En Provence, France
16 As of 2025

Misgav, Israel
 

Shelton, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Graftys Competitors (24)

One of Graftys’s 24 competitors is CoreBone, a Venture Capital-Backed company based in Misgav, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CoreBone Venture Capital-Backed Misgav, Israel
Spine Wave Venture Capital-Backed Shelton, CT
Bonalive Biomaterials Corporation Turku, Finland
DePuy Synthes Corporate Backed or Acquired Warsaw, IN
Graham Medical Technologies Corporate Backed or Acquired Macomb, MI
You’re viewing 5 of 24 competitors. Get the full list »

Graftys Patents

Graftys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3999136-A1 Bone cement with hyaluronic acid Inactive 19-Jul-2019
US-20220273841-A1 Bone cement with hyaluronic acid Inactive 19-Jul-2019
WO-2021013748-A1 Bone cement with hyaluronic acid Inactive 19-Jul-2019
CA-3058931-A1 Phosphocalcic cement composition comprising blood Pending 06-Apr-2016
EP-3228334-A1 Phosphocalcic cement composition comprising blood Inactive 06-Apr-2016 A61L24/12
To view Graftys’s complete patent history, request access »

Graftys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Graftys Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Financière Mirabel Corporation Minority
GO Capital Venture Capital Minority
Incubateur Impulse Accelerator/Incubator Minority
La Financiere viveris PE/Buyout Minority
Noshaq Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Graftys Acquisitions (2)

Graftys’s most recent deal was a Merger/Acquisition with Biologics for life. The deal was made on 15-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biologics for life 15-Nov-2021 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Biologics 4 Life 08-Nov-2021 Merger/Acquisition Biotechnology
To view Graftys’s complete acquisitions history, request access »

Graftys FAQs

  • When was Graftys founded?

    Graftys was founded in 2005.

  • Where is Graftys headquartered?

    Graftys is headquartered in Aix En Provence, France.

  • What is the size of Graftys?

    Graftys has 16 total employees.

  • What industry is Graftys in?

    Graftys’s primary industry is Surgical Devices.

  • Is Graftys a private or public company?

    Graftys is a Private company.

  • What is Graftys’s current revenue?

    The current revenue for Graftys is .

  • How much funding has Graftys raised over time?

    Graftys has raised $20.3M.

  • Who are Graftys’s investors?

    Financière Mirabel, GO Capital, Incubateur Impulse, La Financiere viveris, and Noshaq are 5 of 11 investors who have invested in Graftys.

  • Who are Graftys’s competitors?

    CoreBone, Spine Wave, Bonalive Biomaterials, DePuy Synthes, and Graham Medical Technologies are some of the 24 competitors of Graftys.

  • When was Graftys acquired?

    Graftys was acquired on 01-Jun-2024.

  • Who acquired Graftys?

    Graftys was acquired by Noraker (Therapeutic Devices).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process